Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer
Covered in this story
Analyst targets on Pagerduty Inc
- Morgan Stanley: $9.39 → $9 by Jul 2027 · Underweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pagerduty Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.